Baselga J - Search Results

1

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.

Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J. Morancho B, et al. Among authors: baselga j. Oncogene. 2013 Mar 14;32(11):1452-9. doi: 10.1038/onc.2012.152. Epub 2012 May 28. Oncogene. 2013. PMID: 22641219

2

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J. Baselga J, et al. J Natl Cancer Inst. 1993 Aug 18;85(16):1327-33. doi: 10.1093/jnci/85.16.1327. J Natl Cancer Inst. 1993. PMID: 8340945

3

Autocrine regulation of membrane transforming growth factor-alpha cleavage.

Baselga J, Mendelsohn J, Kim YM, Pandiella A. Baselga J, et al. J Biol Chem. 1996 Feb 9;271(6):3279-84. doi: 10.1074/jbc.271.6.3279. J Biol Chem. 1996. PMID: 8621731 Free article.

4

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

Baselga J, Seidman AD, Rosen PP, Norton L. Baselga J, et al. Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):43-8. Oncology (Williston Park). 1997. PMID: 9110342 Free article. Review.

5

Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing.

Merlos-Suárez A, Fernández-Larrea J, Reddy P, Baselga J, Arribas J. Merlos-Suárez A, et al. Among authors: baselga j. J Biol Chem. 1998 Sep 18;273(38):24955-62. doi: 10.1074/jbc.273.38.24955. J Biol Chem. 1998. PMID: 9733803 Free article.

6

The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP).

Ureña JM, Merlos-Suárez A, Baselga J, Arribas J. Ureña JM, et al. Among authors: baselga j. J Cell Sci. 1999 Mar;112 ( Pt 6):773-84. doi: 10.1242/jcs.112.6.773. J Cell Sci. 1999. PMID: 10036228

7

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Codony-Servat J, et al. Among authors: baselga j. Cancer Res. 1999 Mar 15;59(6):1196-201. Cancer Res. 1999. PMID: 10096547

8

A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface.

Fernández-Larrea J, Merlos-Suárez A, Ureña JM, Baselga J, Arribas J. Fernández-Larrea J, et al. Among authors: baselga j. Mol Cell. 1999 Apr;3(4):423-33. doi: 10.1016/s1097-2765(00)80470-0. Mol Cell. 1999. PMID: 10230395 Free article.

9

Type I receptor tyrosine kinases as targets for therapy in breast cancer.

Baselga J, Mendelsohn J. Baselga J, et al. J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):165-74. doi: 10.1023/a:1026355831693. J Mammary Gland Biol Neoplasia. 1997. PMID: 10882302 Review.

10

The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein.

Borrell-Pagès M, Fernández-Larrea J, Borroto A, Rojo F, Baselga J, Arribas J. Borrell-Pagès M, et al. Among authors: baselga j. Mol Biol Cell. 2000 Dec;11(12):4217-25. doi: 10.1091/mbc.11.12.4217. Mol Biol Cell. 2000. PMID: 11102519 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

585 results

Search Page

Filters